PRESS RELEASE: IVI Responds to ICER’s New Pilot Program

The Institute for Clinical Economic Review (ICER) recently launched a new pilot program that will allow more extensive evaluation of draft economic models used in ICER’s reports. In response to ICER’s new program, Mark Linthicum, Director of Scientific Communications for the Innovation and Value Initiative (IVI), commented: “The Innovation and Value Initiative (IVI) is working diligently […]

PRESS RELEASE: IVI Releases Public Feedback and Technical Expert Panel Recommendations for Open-Source Platform Model to Assess Outcomes and Value of Rheumatoid Arthritis Therapies

Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model Los Angeles, CA – September 20, 2018 — The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the […]

PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value

Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the […]

PRESS RELEASE: IVI Unveils New Value Assessment Model for Non-Small Cell Lung Cancer

IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R […]